Highlights

  • Immuron (ASX:IMC) reported FY26 Travelan sales of $7.7 million, representing year-on-year growth.
  • Travelan delivered four consecutive quarters of higher sales compared with the corresponding periods in the previous year.
  • Australia and the United States remained key commercial markets, supported by retail expansion and Digital Marketing initiatives.
  • The company continues advancing clinical and defence-related programs alongside its commercial product portfolio.

Immuron (ASX:IMC) has continued strengthening its commercial foundation through growth in its flagship Travelan product while progressing a pipeline of biotechnology opportunities across infectious disease and immune-based therapies.

The Melbourne-based biotechnology company recorded its strongest Travelan sales performance in recent years during FY26, supported by improved market presence, digital initiatives and broader customer engagement.

Alongside commercial growth, Immuron continues developing additional opportunities through research partnerships and clinical programs aimed at expanding its long-term product portfolio.

Travelan Growth

Immuron reported global Travelan sales of $7.7 million for FY26, representing growth compared with the previous year.

The company highlighted that each quarter during FY26 delivered higher Travelan sales than the corresponding quarter in the prior year, reflecting continued commercial momentum.

Australia remained the largest contributor, generating $5.8 million in sales during the year. The company attributed growth to expanded retail presence, digital marketing activities, in-store promotions and updated product packaging.

The United States market also contributed positively, with sales increasing during FY26 as Immuron improved product visibility and customer engagement.

Travelan remains the company’s primary commercial product, targeting travellers’ diarrhoea prevention through an oral immunotherapy approach.

Market Expansion

Immuron continues focusing on increasing Travelan adoption across key markets.

In Australia, the company has expanded retail availability and strengthened consumer awareness through targeted marketing activities.

The United States represents an important growth opportunity, with Immuron using online channels and digital platforms to improve product access.

The company is also seeking to expand distribution opportunities while monitoring travel trends and consumer Demand across higher-risk travel destinations.

Alongside Travelan, Immuron continues commercialising ProIBS, a medical device product distributed in Australia and New Zealand under an agreement with Calmino Group.

This provides an additional opportunity to diversify Revenue beyond the company’s core travel health product.

Pipeline Development

Beyond Travelan, Immuron continues advancing its broader biotechnology pipeline.

The company expanded its research relationship with the US Department of Defense, Naval Medical Research Command and Walter Reed Army Institute of Research to develop antibody-based candidates targeting infectious diseases.

The collaboration builds on previous work involving enterotoxigenic E. coli (ETEC) and supports development of additional therapeutic approaches.

The company also continues progressing IMM-529, a candidate targeting Clostridioides difficile infection.

Immuron received FDA clearance for IMM-529 to proceed under an Investigational New Drug application and is seeking potential partners to support future clinical development.

Clinical Progress

Immuron’s clinical pipeline has experienced both progress and challenges.

A Phase 2 military study evaluating an ETEC-targeted colostrum product did not achieve its primary endpoint. The company highlighted differences between the tested formulation and Travelan’s approved commercial formulation, while continuing discussions regarding future development pathways.

The outcome demonstrated the challenges associated with advancing new therapeutic applications, even as the commercial Travelan product continues generating revenue.

Future progress across clinical programs will depend on regulatory outcomes, partnerships and available funding.

Key Focus Areas

Investors will continue monitoring whether Travelan sales growth can continue into FY27 and contribute towards improving cash generation.

The company’s ability to secure partnerships for pipeline assets, particularly IMM-529, will also remain an important area of focus.

Progress across defence-related research programs and potential additional funding opportunities may provide further support for pipeline development.

The company’s upcoming financial disclosures will provide further insight into cash position, operating performance and Investment requirements.

Risks

Immuron remains a small biotechnology company operating across both commercial and development-stage activities.

Clinical development programs involve significant uncertainty, including regulatory approval requirements, trial outcomes and the ability to secure future funding.

The company remains dependent on Manufacturing partners, research collaborations and commercial distribution relationships.

While Travelan provides an established revenue base, continued growth depends on maintaining customer demand and expanding market reach.

As a small-cap healthcare company, Immuron may also experience increased share price Volatility due to clinical updates, funding decisions and commercial developments.

Future Outlook

Immuron enters FY27 with improving commercial momentum from Travelan and several longer-term opportunities across its biotechnology pipeline.

The continued growth of Travelan sales provides a stronger foundation for the business, while research programs and potential partnerships could create additional value over time.

The company’s next phase will depend on sustaining consumer product growth, advancing clinical programs and managing Capital requirements effectively.

With Travelan delivering consistent year-on-year growth and pipeline initiatives progressing, Immuron’s ability to convert commercial momentum into broader financial strength will remain the key focus for investors.